Source: Investing.com ↗

Oppenheimer initiates Aktis Oncology stock rating at Outperform

|

Translation unavailable. Please try again.

Original report

Read the original report on Investing.com ↗

Recommended markets

No specific asset was identified in this report; browse live USDT reference pairs.

Browse markets →

USDC/USDT

$1.00

-0.02%

BTC/USDT

$86,184.01

+0.89%

ETH/USDT

$2,747.40

+0.86%

ZEC/USDT

$1,622.74

+7.80%

XRP/USDT

$1.61

+6.28%